Mortality at maximal · participants with alcoholic hepatitis (all severity)
It is very uncertain whether glucocorticosteroids changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether glucocorticosteroids changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
1 finding from 1 review
Mortality at maximal · participants with severe alcoholic hepatitis
It is very uncertain whether glucocorticosteroids changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · participants with severe alcoholic hepatitis
It is very uncertain whether glucocorticosteroids changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · participants with severe alcoholic hepatitis
It is very uncertain whether glucocorticosteroids changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (number) · participants with severe alcoholic hepatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether glucocorticosteroids changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · participants with severe alcoholic hepatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Daclizumab plus glucocorticosteroids (3 RCTs; 927 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes daclizumab plus glucocorticosteroids (3 RCTs; 927 participants) (very low certainty).
1 finding from 1 review
HR 1.27 [0.49, 3.75]
Studies not reported
Very low
Intervention not reported
Basiliximab plus glucocorticosteroids (2 RCTs; 528 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes basiliximab plus glucocorticosteroids (2 RCTs; 528 participants) (very low certainty).
1 finding from 1 review
OR 1 [0.67, 1.47]
Studies not reported
Very low
Intervention not reported
Daclizumab plus glucocorticosteroids (2 RCTs; 897 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes daclizumab plus glucocorticosteroids (2 RCTs; 897 participants) (very low certainty).
1 finding from 1 review
OR 0.87 [0.65, 1.15]
Studies not reported
Very low
Intervention not reported
Anti‐thymocyte globulin plus glucocorticosteroids (1 RCT; 37 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes anti‐thymocyte globulin plus glucocorticosteroids (1 RCT; 37… (very low certainty).
1 finding from 1 review
Intervention not reported
Daclizumab plus glucocorticosteroids (1 RCT; 148 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes daclizumab plus glucocorticosteroids (1 RCT; 148 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Daclizumab plus glucocorticosteroids (1 RCT; 698 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes daclizumab plus glucocorticosteroids (1 RCT; 698 participants) (very low certainty).
1 finding from 1 review
HR 1.11 [0.44, 2.78]
Studies not reported
Very low
Intervention not reported
Glucocorticosteroids · adults undergoing liver transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Basiliximab plus glucocorticosteroids (1 RCT; 381 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes basiliximab plus glucocorticosteroids (1 RCT; 381 participants) (very low certainty).
1 finding from 1 review
OR 0.98 [0.02, 38.67]
Studies not reported
Very low
Intervention not reported
Anti‐thymocyte globulin plus glucocorticosteroids (1 RCT; 93 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes anti‐thymocyte globulin plus glucocorticosteroids (1 RCT; 93… (very low certainty).
1 finding from 1 review
Intervention not reported
Daclizumab plus glucocorticosteroids (3 RCTs; 1045 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes daclizumab plus glucocorticosteroids (3 RCTs; 1045 participants) (very low certainty).
1 finding from 1 review
HR 1.26 [0.66, 2.42]
Studies not reported
Very low